C13orf16 Inhibitors is a class of compounds specifically designed to modulate the function or activity of the protein encoded by the C13orf16 gene, also known as TEX29. This protein is believed to have roles in specific cellular processes, and the inhibition of its function could provide insights into its biological significance and the broader cellular pathways in which it participates.
The mechanism by which C13orf16 Inhibitors function is dependent on the molecular nature and structure of the protein itself. For proteins with enzymatic activity, inhibitors typically bind to the active site, preventing the substrate from interacting and thus halting the enzyme's action. However, for proteins that act as scaffolds or interaction partners for other proteins, inhibitors might function by preventing these protein-protein interactions. Such a mechanism might involve the inhibitor binding to an allosteric site, a region on the protein separate from its main functional site, causing a conformational change that makes interaction with its regular partners impossible. In some cases, inhibitors can also bind covalently to the target protein, leading to irreversible inhibition. The design and specificity of C13orf16 Inhibitors would largely hinge on the specific structural and functional attributes of the C13orf16 protein. Through careful molecular design and biochemical testing, researchers can tailor these inhibitors to achieve optimal binding affinity and specificity, ensuring minimal off-target effects.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Binds to the active site of certain kinases, preventing interaction with natural ligands. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Allosteric inhibitor that binds mTOR, inducing a conformational change and altering its function. | ||||||
α-Iodoacetamide | 144-48-9 | sc-203320 | 25 g | $255.00 | 1 | |
Binds covalently to cysteine residues in proteins, potentially rendering them inactive. | ||||||
Trifluoperazine Dihydrochloride | 440-17-5 | sc-201498 sc-201498A | 1 g 5 g | $57.00 $101.00 | 9 | |
Targets a regulatory domain (Calmodulin), inhibiting its activation or interaction with partner proteins. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Inhibits the activity of protein phosphatases, which could affect post-translational modifications. | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
Blocks the binding pocket of some proteins, preventing them from interacting with cellular partners. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
Forms a stable complex with RNA polymerase II, preventing its transcriptional activity. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Interacts with the transport protein complex and prevents protein dimerization in the Golgi apparatus. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Induces degradation of proteins through the ubiquitin-proteasome pathway. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Interferes with the folding of newly synthesized proteins, leading to their misfolding and loss of function (specifically N-linked glycosylation). | ||||||